EULAR REPORT

EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees

I RATIONALE OF STANDARDISED OPERATING PROCEDURES
It is the objective of the EULAR executive committee to promote actions and/or projects aimed at improving the knowledge and/or the recognition of musculoskeletal disorders.

The chief aim is to contribute to the improvement of outcome of patients with rheumatic disorders. Apart from the projects devoted to education and research, projects aimed at facilitating the conduct of clinical studies or at improving the management of musculoskeletal disorders are welcome. Such studies can be categorised in four sections:

- Studies dedicated to a proposal for classification and/or diagnostic criteria
- Recommendations for designing and/or conducting clinical trials in specific musculoskeletal disorders
- Recommendations for monitoring and/or management and/or treatment of specific musculoskeletal disorders
- Standardisation of (laboratory and other) procedures.

II METHODOLOGICAL AND PRACTICAL ASPECTS
At each step of such projects (application, elaboration, dissemination, etc), the individual items summarised in table 1 should be discussed. The reader is invited to visit the EULAR website (http://www.eular.org) to check the most recently updated version of these procedures.

A Which wording?
The three proposals are “points to consider”, “recommendations”, “guidelines”.

It is the opinion of the EULAR executive committee members that, on the one hand, “guidelines” might appear too constraining and that, on the other hand, “points to consider” might be considered as too open. Recommendations can be considered as advice for performing the task/action, when applicable, as a marker of quality.

The choice of wording should be based on the content of each project. For example, one can suggest that if an evidence based approach fully answers the question, “guidelines” can be proposed, but if an approach fails to reach any conclusion, “points to consider” should be preferred.

B Which category?
As previously mentioned, it is expected that these procedures could be applied to studies proposing:

- Recommendations for conducting clinical studies and/or clinical trials
- Recommendations for management, monitoring, or treatment in daily practice
- Recommendations for standardisation of other procedures.

C Objectives
The objectives of the project should be made clear from the beginning.

The definition of the target population (the population interested in such project) will facilitate the different steps of the project from its design to its implementation.

For example, a target population might be defined as:

- Rheumatologists
- General practitioners
- Health professionals
- National and/or international drug agencies
- Drug companies
- Others.

In practice, one single project can have several target populations. However, the presentation, dissemination, evaluation, and implementation may be different for each subcategory of the target population.

D Steering group members
Four categories of people will have to be included in each project.

1 The convenor of the project
This person (one person), preferably not a member of the EULAR executive committee, will be the link between the project group and the EULAR organisation.

It is expected that such a convenor will be also the chairperson of the project because he/she has a high level of experience in the field of interest of the project.

2 The experts
Such people should be representatives of the European rheumatological community.

They should come from at least three different European countries. However, top leaders in the field, including non-rheumatologists, should be invited even if they come from outside the European community.

It is expected that these experts have an academic position, but they can also have other positions and be invited as...
experts because of their high level of expertise in this field (for example, national agencies and/or drug company representatives).

3 A clinical epidemiologist
To promote a high level of quality and homogeneity of methodological issues in all projects, each study steering group should include an expert in clinical epidemiology (preferably not a member of the EULAR executive committee). If needed, the chair of the EULAR Standing Committee on Epidemiology or the chair of ECSICT will help in identifying such experts.

The clinical epidemiologist will attend at least the first meeting of the steering committee members and will be in charge of following up the project during its different steps.

4 The person in charge of the literature research
It is expected that for most projects a systematic literature research will be mandatory.

This research can be performed by a person outside the steering group under the supervision of the convenor and/or a designated member of the steering committee.

E Evidence based approach
1 Literature search strategy
If applicable, such strategy should include two parts, which have to be decided before performing the literature search.

a) Selection of specific modalities
For a specific project (for example, management of knee osteoarthritis), it has to be decided whether the literature search will be focused on specific domains (for example, pharmacological treatment modalities). A reference to a specific scoring system is given in Appendix 1.

This decision will permit keywords to be clearly defined, which will be the starting point of the literature research.

b) Techniques of the literature search
Each project should clearly describe the different databases explored in the literature search (for example, Medline, PubMed, etc). It is strongly recommended that the Cochrane Library is included in every search for treatments.

2 Quality scoring of the manuscripts
The methodology used for scoring the different evaluated manuscripts (quantity, quality) has to be precisely described. The following practical decision can be expected:

- To describe only the number of evaluated manuscripts
- To categorise each evaluated manuscript (for example, placebo randomised controlled trial, randomised controlled trial, prospective versus retrospective, etc)
- To score each evaluated manuscript. For this purpose, several scoring systems have been proposed—in particular, for evaluation of the report of therapeutic trials. The choice of scoring system should take into account the nature of the project (in particular, pharmacological versus non-pharmacological treatment modalities). A reference to a specific scoring system is given in Appendix 1.

3 Estimation of the relevance of the evaluated item
We can anticipate four situations.

a) Evaluation of treatment modalities
To obtain an objective evaluation of different treatment modalities one might consider it of interest to quantify treatment effects.

For example, in knee osteoarthritis, the decision has been taken to focus on a single variable (pain) and thereafter to present the results as either effect size (for the continuous variables) or number needed to treat (for the dichotomous variables). If the dichotomous variable is chosen (for example, responder yes/no, success yes/no) and if the domain (for example, pain) has been evaluated by using a continuous variable (for example, change in a 0–100 mm visual analogue scale), a cut off point has to be decided a priori (for example, improvement of at least 30% in pain will be defined as a success).

b) Evaluation of outcome variables
In a project aimed at proposing recommendations on the design and conduct of clinical trials in a specific musculo-skeletal disease, one might consider it interesting to evaluate the performance of different proposed outcome measures (for example, face validity, reliability, sensitivity to change, and discriminant capacity, etc).

### Table 1 Points to consider for the application of a study focused on recommendations in order to obtain EULAR endorsement

<table>
<thead>
<tr>
<th>Category</th>
<th>Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Which wording?</td>
<td>(points to consider versus recommendations versus guidelines)</td>
</tr>
<tr>
<td>B. Which category?</td>
<td>(management versus treatment versus conducting studies)</td>
</tr>
<tr>
<td>C. Objectives?</td>
<td>(which target population: GP versus rheumatologists versus health professionals...)</td>
</tr>
<tr>
<td>D. Steering group committee members (who is participating in this project)?</td>
<td></td>
</tr>
<tr>
<td>E. Evidence based review</td>
<td></td>
</tr>
<tr>
<td>- Literature research strategy</td>
<td></td>
</tr>
<tr>
<td>- Quality scoring of the manuscripts</td>
<td></td>
</tr>
<tr>
<td>- Estimating a &quot;treatment/criterion&quot; effect size</td>
<td></td>
</tr>
<tr>
<td>- Categorising evidence</td>
<td></td>
</tr>
<tr>
<td>- Strength of recommendations</td>
<td></td>
</tr>
<tr>
<td>F. Evidence based versus expert opinion approach</td>
<td></td>
</tr>
<tr>
<td>G. Presentation of the recommendations (algorithm versus bullet versus ...)</td>
<td></td>
</tr>
<tr>
<td>H. Relevance of the recommendations:</td>
<td></td>
</tr>
<tr>
<td>- Which expected study(ies)?</td>
<td></td>
</tr>
<tr>
<td>- Which methodology?</td>
<td></td>
</tr>
<tr>
<td>I. Dissemination of the recommendations</td>
<td></td>
</tr>
<tr>
<td>- Presentation at different meetings</td>
<td></td>
</tr>
<tr>
<td>- Publication of a manuscript in a peer review journal—for example, EULAR journal</td>
<td></td>
</tr>
<tr>
<td>J. Implementation of the recommendations</td>
<td></td>
</tr>
<tr>
<td>- How can such recommendations impact daily practice?</td>
<td></td>
</tr>
<tr>
<td>- Which expected study(ies)?</td>
<td></td>
</tr>
<tr>
<td>- Which methodology?</td>
<td></td>
</tr>
<tr>
<td>K. Update policy of the recommendations</td>
<td></td>
</tr>
<tr>
<td>- When will such recommendations be updated?</td>
<td></td>
</tr>
<tr>
<td>L. Practical aspects</td>
<td></td>
</tr>
<tr>
<td>- Organisation (meetings, research, time lag)</td>
<td></td>
</tr>
<tr>
<td>- Financial support</td>
<td></td>
</tr>
</tbody>
</table>
Presenting the results using different short sentences

Presenting the results using an algorithm (tree decision)

Two main categories have been proposed:

- Monitoring/treatment-specific disorders

Example of recommendations for management/treatment modality and/or the population. For example, interpretation of the effect size of a treatment alone may be too complicated to be fully used by the target population. It is admitted that publication of the evidence based approach is only based on a systematic literature research and the strength of recommendations also takes into account the knowledge of the experts. The strategy permitting use of the category “strength of recommendations” should be clearly described in the project (for example, vote of the experts after getting the results of the literature research).

Categorising evidence

Categorising evidence has been clearly defined for the treatment modalities. Table 2 summarises these categories.

This categorisation has to be given for each recommendation of the treatment modality.

Strength of recommendations

The strength of recommendations is clearly defined for the important factors of the treatment modalities. Table 3 summarises these categories.

The main difference between “categories of evidence” and “strength of recommendations” is that the category of evidence is only based on a systematic literature research and the strength of recommendations also takes into account the knowledge of the experts. The strategy permitting use of the category “strength of recommendations” should be clearly described in the project (for example, vote of the experts after getting the results of the literature research).

Expert opinion approach

It is admitted that publication of the evidence based approach alone may be too complicated to be fully used by the target population. For example, interpretation of the effect size of a treatment modality and/or the $k$ coefficient for the reliability of an outcome measure requires a specific knowledge.

Thus to make it clear, the recommendations may include summary statements from the experts based on the reported evidence or personal experience. Such expert opinion should appear only after or in parallel to an evidence based approach but never alone. Contents derived from expert opinion should be clearly identified, together with the reasons for that approach.

Presentation of recommendations

Example of recommendations for management/monitoring/treatment-specific disorders

Two main categories have been proposed:

- Presenting the results using an algorithm (tree decision)
- Presenting the results using different short sentences (bullets, take home messages).

Whatever the decision, dissemination of the recommendations will be highly facilitated if the presentation is as simple as possible.

<table>
<thead>
<tr>
<th>Table 3</th>
<th>Strength of recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strength</td>
<td>Directly based on:</td>
</tr>
<tr>
<td>A</td>
<td>Category I evidence</td>
</tr>
<tr>
<td>B</td>
<td>Category II evidence or extrapolated recommendations from category I evidence</td>
</tr>
<tr>
<td>C</td>
<td>Category III evidence or extrapolated recommendation from category I or II evidence</td>
</tr>
<tr>
<td>D</td>
<td>Category IV evidence or extrapolated recommendation from category II or III evidence</td>
</tr>
</tbody>
</table>

Evaluation of a proposed criterion

In a project aimed at proposing classification criteria (for example, definition of the disease at entry into a clinical trial), one might consider it important to evaluate also the performance of a set of criteria (for example, sensitivity, specificity, pre- and post-test probability).

Recommendations

It is strongly suggested that recommendation should only be made on the basis of homogeneous and quantifiable information.

Categorising evidence

Categorising evidence has been clearly defined for the treatment modalities. Table 2 summarises these categories.

This categorisation has to be given for each recommendation of the treatment modality.

Strength of recommendations

The strength of recommendations is clearly defined for the important factors of the treatment modalities. Table 3 summarises these categories.

Sample size calculation

- The known (or unknown) expected placebo (and/or conventional treatment) effect.
- The clinically relevant expected treatment effect (differences between the study treatment and the control treatment).

Relevance of the recommendations

- If applicable, this evaluation has to be planned from the beginning of the project.
- An “external” evaluation can be easily performed according to the AGREE instrument. A paper version of this instrument is available on demand for current projects at the ECSICIT secretariat. Such an instrument is also available on the web at http://www.agreecollaboration.org
- The evaluation can also be performed at the level of the target population. For example, one survey can be performed to check whether the proposed recommendations of a treatment are in accordance with the daily practice of the target population (for example, general practitioners). For the conduct of clinical studies, these recommendations can be presented and discussed at a meeting to which health agencies and drug company representatives are invited.
- The evaluation should also deal with the potential use of the proposed recommendations for teaching rheumatology (medical schools, postgraduate training, health professional schools, etc).
- Such evaluation could be developed as a specific project.

Dissemination of the recommendations

Strategies for disseminating the proposed recommendation to the target population should be included in the project. Whatever the project, the steering group is expected to:

- Submit an abstract for presentation at the annual EULAR scientific meeting
- Submit a manuscript for publication in the EULAR journal.
J Implementation of the recommendations
It is the goal of recommendations to change practices and allow them to converge towards harmonisation. Implementation is the process by which targeted users (researchers or clinicians) integrate the actions recommended into their practice. Efficient implementation leads to successful changes.

However, it is worth assessing the potential impact of the proposed recommendations in daily practice because this is dependent on the degree of implementation. On the one hand, one might consider that any project aimed at either evaluating and/or disseminating the proposed recommendations will have an impact on daily practice. On the other hand, some studies suggest that the dissemination of recommendations is not sufficient to achieve such an impact. Several other techniques have been proposed:

- Opinion leaders
- Outcome visits or academic detailing
- Audit feedback
- Continuing medical education
- Reminder (paper print reminders, electronic reminders, phone call reminders).

Detailed information about the efficacy of the different techniques (including references related to the above techniques) in implementing the medical recommendations is available (in French but with references in English) on the web at the following address: http://www.anaes.fr

Such an evaluation might be developed as a specific project.

K Update policy of the recommendations
During the process of producing recommendations, one should expect to answer the following questions:

- Do proponents expect an update of the proposed recommendations?
- If yes, when? How? By whom?

I Practical and financial aspects of the project
1 Practical aspects
It is expected that each project will require the following:

a) Meeting(s) of the steering group members
For each project, the following information will be required at the start:

- Number of planned meetings
- Number of people who will attend such meeting(s)
- A calendar of the planned meetings.

As soon as the project is endorsed by EULAR (see below), the secretariat of EULAR will take care of the practical aspects of these meetings (hotel reservation, meeting room reservation, travel expenses).

b) Fellowship for the literature research
If possible, this fellow has to be designated before the first meeting of the steering group. The amount of time (full versus part time) and the duration of his/her work has to be proposed.

1 Financial aspects
The budget of each project will include:

- Organisation of the meetings of the steering group (hotel reservation, travel expenses)
- A grant for the fellow in charge of the literature research, if necessary
- A grant for the statistical analysis, if necessary

Table 4 Scoring system

<table>
<thead>
<tr>
<th>No</th>
<th>Items</th>
<th>Score</th>
<th>Yes</th>
<th>No</th>
<th>Total†</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Are the hypothesis/aims/objectives described?</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td>Are outcomes described in the introduction or methods?</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td>Are the patient inclusion/exclusion criteria outlined?</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.</td>
<td>Is the intervention described?</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.</td>
<td>Are the age/weight/sex/disease characteristics recorded?</td>
<td>2 (1)*</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6.</td>
<td>Are the main findings in simple outcome data?</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.</td>
<td>Are there estimates of random variability?</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.</td>
<td>Is there measurement of adverse events?</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.</td>
<td>Are the characteristics of subjects lost to follow up described?</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.</td>
<td>Have actual probability values been reported?</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.</td>
<td>Is the source of the subject recruitment recorded?</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.</td>
<td>Is the proportion of subjects willing to participate recorded?</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.</td>
<td>Were the staff, places, and facilities representative?</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.</td>
<td>Are the study subjects “blinded”?</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.</td>
<td>Are those measuring the main outcome blinded?</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.</td>
<td>Are all the outcomes described in the results referenced in the introduction/methods?</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.</td>
<td>Are there adjustments for different lengths of follow up?</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.</td>
<td>Are the statistical tests appropriate?</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.</td>
<td>Is compliance with the intervention monitored?</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20.</td>
<td>Were the outcome measures used clearly described?</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21.</td>
<td>Are the patient characteristics similar between groups?</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>22.</td>
<td>Were the subjects recruited over the same time period?</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>23.</td>
<td>Were the study subjects randomised to intervention groups?</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24.</td>
<td>Was the randomisation assignment concealed from subjects and staff?</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25.</td>
<td>Was there an attempt to adjust for significant differences in subjects’ age/weight/sex/main disease characteristics between intervention groups?</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>26.</td>
<td>Were losses of subjects to follow up taken into account?</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>27.</td>
<td>Did the study calculate the number of subjects required to provide sufficient data?</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*1 = partial information; †score range = 0, worst to 28, best.
A grant for the secretariat of the steering committee, if necessary.

There will be no honorarium for participation of the experts.

**M EULAR endorsement policy**

Endorsement by EULAR should be sought according to the EULAR procedures (see the EULAR website). In summary, the first steps are to get such an endorsement after submission of an application to the appropriate EULAR standing committee taking into account the different points summarised in table 1.

This EULAR endorsement will permit the project to start but could still be cancelled if there are any deviations from the present procedure during the different steps of the project. For examination of possible deviations the clinical epidemiologist in charge of the project will have to send to the chairman of the appropriate standing committee a report after each meeting of the steering committee. Moreover, the material (abstract, manuscript) planned for publication should receive the approval of the chairman of the appropriate standing committee before any submission is made.

**M Dougados,**
Clinique de Rhumatologie B Groupe, Hospitalier Cochin, Paris 75014, France

**N Betteridge,**
Arthritis Care, 18 Stephenson Way, London NW1 2HD, UK

**G R Burmester,**
Department of Rheumatology and Clinical Immunology, Charité Humboldt University, Schumanstrasse 20–21, D 10117 Berlin, Germany

**L Euller-Ziegler,**
Service de Rhumatologie, Archet Hospital, route de Saint-Antoine Ginestiere, 06202 Nice, Cedex 3, France

**F Guillemin,**
Ecole de Sante Publique, Faculté de Médecine, BP 184, 54505 Vandoeuvre les Nancy, France

**J Hirvonen,**
Suomen Reumatitty, Iso Roobertinkatu 20–22A, Helsinki FIN-01200, Finland

**J Lloyd,**
Brunel University, Department of Health Studies, Borough Rd, Isleworth TW7 5DU, UK

**S Ozen,**
Hacettepe University, Department of Paediatrics, 06100 Ankara, Turkey

**J A P De Silva,**
Nucleo de Reumatologia, Hospitalais de Universidade de Coimbra, Servicio de Medicina III et Reumatologia, 3000-075 Coimbra, Portugal

**P Emery,**
Academic Unit of Musculoskeletal Diseases, Department of Rheumatology, 1st Floor, Leeds LS1 3EX, UK

**J R Kalden,**
Institut for Clinical Immun & Rheumatism, University Erlangen-Nuremberg, Krakenhausstrasse 2, Erlangen 91054, Germany

**T Kvien,**
Oslo City Department of Rheumatology, Diakonhjemmet Hospital, PO Box 23 Vinderen, Oslo N 0319, Norway

**M Matucci-Cerinic,**
Department Medicine/Division of Rheumatology, University of Florence, Villa Monna Tessa, Viale Pleraccini 18, Florence 50139, Italy

**J Smolen,**
Aligemeines Krankenhaus, Klinik für Innere Medizin II, Klinische Abteilung für Rheumatologie, Wahringer Gürtel 18–20, Vienna 1090, Austria

Correspondence to: Professor M Dougados;
maxime.dougados@cch.ap-hop-paris.fr

**APPENDIX 1**
Table 4 shows an example of a scoring system of a manuscript summarising the results of a therapeutic trial.1

**Reference**
EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees

M Dougados, N Betteridge, G R Burmester, L Euler-Ziegler, F Guillaume, J Hirvonen, J Lloyd, S Ozen, J A P Da Silva, P Emery, J R Kalden, T Kvien, M Matucci-Cerinic and J Smolen

Ann Rheum Dis 2004 63: 1172-1176
doi: 10.1136/ard.2004.023697

Updated information and services can be found at:
http://ard.bmj.com/content/63/9/1172

These include:

References
This article cites 1 articles, 1 of which you can access for free at:
http://ard.bmj.com/content/63/9/1172#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Musculoskeletal syndromes (4951)
Connective tissue disease (4253)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/